Literature DB >> 33303972

SMAD4 mutation correlates with poor prognosis in non-small cell lung cancer.

Yue Wang1,2, Qianqian Xue1,2, Qiang Zheng1,2, Yan Jin1,2, Xuxia Shen1,2, Mu Yang3, Xiaoyan Zhou1,2, Yuan Li4,5.   

Abstract

SMAD4 is an intracellular signaling mediator of the TGF-β pathway. Its mutation was commonly observed in gastrointestinal cancers, such as pancreatic cancer. The loss of SMAD4 on immunohistochemical staining is often used to suggest a pancreaticobiliary differentiation in evaluating a metastatic adenocarcinoma with unknown origin. However, the function and molecular mechanism of SMAD4 in non-small cell lung cancer (NSCLC) development are largely unknown. Thus, we studied the correlation between SMAD4 mutations and clinico-molecular features in the patients with NSCLC. We reported the frequencies and prognostic values of SMAD4 mutations in a Chinese NSCLC cohort using next-generation sequencing. The NSCLC cases from several public databases, including The Cancer Genome Atlas and others, were also used in this study to elucidate SMAD4-related molecular partners and mechanisms. Integrated bioinformatics analyses were conducted, such as analysis of Gene Ontology enrichment analysis, gene set enrichment analysis (GSEA), and survival analysis. Immunohistochemistry showed that the tissues harboring SMAD4 mutations tended to show SMAD4 deficiency or loss, while SMAD4 expression was significantly reduced at all stages of NSCLC cases. We found that reduced SMAD4 expression was more frequent in the patients with poor disease-free survival and resistance to platinum-based chemotherapy. SMAD4 mutation was an independent risk factor for the survival of NSCLC patients. The expression of SMAD4 was associated with that of SMAD2. The GSEA showed that SMAD4 might promote NSCLC progression by regulating proliferation, adhesion, and immune response. In conclusion, these data suggest that SMAD4 mutation or loss as well as reduced expression can be used to identify the NSCLC patients with poor survival and resistance to platinum-based chemotherapy. SMAD4 may be a predictive marker or therapeutic target in NSCLC. The source code and user's guide are freely available at Github: https://github.com/wangyue77-ab/smad4 .

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33303972     DOI: 10.1038/s41374-020-00517-x

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  50 in total

1.  Structural and functional analysis of SMAD4 gene promoter in malignant pancreatic and colorectal tissues: detection of two novel polymorphic nucleotide repeats.

Authors:  Aleksandra Nikolic; Snezana Kojic; Srbislav Knezevic; Zoran Krivokapic; Momcilo Ristanovic; Dragica Radojkovic
Journal:  Cancer Epidemiol       Date:  2010-10-30       Impact factor: 2.984

2.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4.

Authors:  A Morén; S Itoh; A Moustakas; P Dijke; C H Heldin
Journal:  Oncogene       Date:  2000-09-07       Impact factor: 9.867

5.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

6.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

Review 7.  Current status of immunotherapy.

Authors:  Susumu Suzuki; Takashi Ishida; Kazuhiro Yoshikawa; Ryuzo Ueda
Journal:  Jpn J Clin Oncol       Date:  2016-01-26       Impact factor: 3.019

Review 8.  The roles of TGFβ in the tumour microenvironment.

Authors:  Michael Pickup; Sergey Novitskiy; Harold L Moses
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

9.  SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer.

Authors:  Nicholas I Fleming; Robert N Jorissen; Dmitri Mouradov; Michael Christie; Anuratha Sakthianandeswaren; Michelle Palmieri; Fiona Day; Shan Li; Cary Tsui; Lara Lipton; Jayesh Desai; Ian T Jones; Stephen McLaughlin; Robyn L Ward; Nicholas J Hawkins; Andrew R Ruszkiewicz; James Moore; Hong-Jian Zhu; John M Mariadason; Antony W Burgess; Dana Busam; Qi Zhao; Robert L Strausberg; Peter Gibbs; Oliver M Sieber
Journal:  Cancer Res       Date:  2012-11-08       Impact factor: 12.701

10.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

View more
  4 in total

1.  LINC02381, a sponge of miR-21, weakens osteogenic differentiation of hUC-MSCs through KLF12-mediated Wnt4 transcriptional repression.

Authors:  Gang Zhao; Wen-Dong Luo; Yong Yuan; Feng Lin; Li-Min Guo; Jing-Jing Ma; Han-Bo Chen; Huang Tang; Jun Shu
Journal:  J Bone Miner Metab       Date:  2021-11-15       Impact factor: 2.626

Review 2.  Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer.

Authors:  Sawsan Rashdan; Puneeth Iyengar; John D Minna; David E Gerber
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Yonglin Yi; Zhengang Qiu; Zifu Yao; Anqi Lin; Yimin Qin; Ruizhan Sha; Ting Wei; Yanru Wang; Quan Cheng; Jian Zhang; Peng Luo; Weitao Shen
Journal:  Front Cell Dev Biol       Date:  2022-01-11

Review 4.  Multiple roles of mothers against decapentaplegic homolog 4 in tumorigenesis, stem cells, drug resistance, and cancer therapy.

Authors:  Chuan-Jing Dai; Yu-Ting Cao; Fang Huang; Yi-Gang Wang
Journal:  World J Stem Cells       Date:  2022-01-26       Impact factor: 5.326

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.